WOODLAND PARK, N.J. & LAKE FOREST, Calif.– Summit Health, part of VillageMD, has announced the internalization of advanced genomic testing capabilities in partnership with Genomic Testing Cooperative (GTC), a global leader in RNA-based diagnostics. The newly launched next-generation sequencing (NGS) laboratory at Summit Health’s Woodland Park, New Jersey facility will enable in-house DNA and RNA profiling for solid tumors and hematologic neoplasms using both tissue and liquid biopsies.
The integration of GTC’s state-of-the-art diagnostic platform marks a significant advancement for Summit Health’s precision medicine capabilities. The new lab will offer GTC’s full menu of tests, including Liquid Trace, a proprietary liquid biopsy assay that analyzes cell-free DNA (cfDNA) and RNA (cfRNA) from blood and cerebrospinal fluid (CSF). The service supports both cancer diagnosis and monitoring, allowing for more comprehensive and timely care.
By conducting these sophisticated genomic tests on-site, Summit Health aims to reduce dependency on external laboratories, standardize data collection, accelerate turnaround times, and enable deeper participation in research and clinical trials. The move also opens opportunities for developing intellectual property and expanding Summit’s footprint in the growing field of precision oncology.
“We are thrilled to partner with GTC in adopting their comprehensive portfolio of genomic testing for hematologic and solid tumors,” said Dr. Gordana Katava, DO, Chief of Pathology and Laboratory Medicine at Summit Health/VillageMD. “These tools are essential for delivering precision medicine, and internalizing them ensures our patients receive timely, personalized treatment based on the latest science.”
As a member of GTC’s national Co-Op group, Summit Health gains access to a pipeline of diagnostic innovation, proprietary datasets, and advanced AI-based software. This collaboration supports a broader effort to democratize genomic testing by making it more accessible and cost-effective for health systems and providers.
Dr. Maher Albitar, Founder and CEO of GTC, highlighted the significance of the partnership. “GTC was founded on the vision of bringing next-generation sequencing to the frontlines of care. By joining our Co-Op model, Summit and VillageMD are helping us realize that goal—standardizing NGS testing, fostering scientific collaboration, and driving down costs while improving care.”
The ribbon-cutting ceremony for the new laboratory reflects Summit Health’s continued investment in innovation and a future where personalized, data-driven cancer treatment is the standard of care.
